1. The Management of Prostatic Obstruction: How to Determine the Best Options? 
C.G Roehrborn, T McNicholas 
European Urology Supplements 
Volume 2, Issue 8, Pages (November 2003)
DOI: /j.eursup

2. Fig. 1
Cumulative treatment discontinuation rates in men with benign prostatic hyperplasia in individual studies [2].
European Urology Supplements 2003 2, 13-19DOI: ( /j.eursup )

3. Fig. 2
Greater suppression of dihydrotestosterone (DHT) levels achieved with dutasteride (Dut) versus finasteride (Fin).
European Urology Supplements 2003 2, 13-19DOI: ( /j.eursup )

4. Fig. 3
Pooled adjusted mean change from baseline in American Urological Symptom Index (AUA-SI) with dutasteride and placebo. Reproduced with permission Roehrborn CG et al. Urology 2002;60:434–441.
European Urology Supplements 2003 2, 13-19DOI: ( /j.eursup )

5. Fig. 4
Pooled adjusted mean change from baseline in prostate volume with dutasteride and placebo.
European Urology Supplements 2003 2, 13-19DOI: ( /j.eursup )

6. Fig. 5
Pooled data for the first episode of acute urinary retention (AUR). Reproduced with permission Roehrborn CG et al. Urology 2002;60:434–441.
European Urology Supplements 2003 2, 13-19DOI: ( /j.eursup )